At a glance
ClinicalIndex Comparison RecordN/ACompleted· 89 enrolled
Drug / intervention
Testican-1other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Diagnostic Role of Serum Testican and Ubiquitin Levels in Patients With Head Trauma
Kanuni Sultan Suleyman Training and Research Hospital·observational·Posted Aug 5, 2024·Updated Aug 5, 2024
In Brief
An observational study evaluating Testican-1 for Moderate Traumatic Brain Injury and 2 related conditions. Completed, enrolled 89 participants across 1 site.
Detailed Summary
We aimed to determine if testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course (presence of intraparenchymal pathology) and mortality in patients with moderate traumatic brain injury.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsModerate Traumatic Brain Injury, Testican-1, Ubiquitin
CountriesTurkey (Türkiye)
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartOct 2020
Primary CompletionMar 2021
Study CompletionApr 2021
First PostedAug 2024
TodayJul 2026
First PostedAug 5, 2024
Enrollment StartOct 1, 2020
Primary CompletionMar 31, 2021
Study CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 1.9 years ago
Interventions
Testican-1other
Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.